Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

Shares of Hoth Therapeutics (HOTH) surged 81.4% on Sept. 5, after the company announced positive data from the treatment of the first patient with its lead candidate, HT-001, who was experiencing papulopustular eruptions (PPEs). Notably, PPEs are a common and debilitating side effect of EGFR inhibitor (EGFRI) therapy in cancer patients. Hoth's HT-001 Demonstrates Superior Efficacy in PPEs Treatment In this groundbreaking case, the 59-year-old female patient undergoing treatment for metastatic breast cancer ...